Extracorporeal CO(2) elimination for acute exacerbation of severe COPD requiring invasive mechanical ventilation: a randomized controlled trial (the X-COPD trial)

Asthma

Dupilumab Improves Lung Function and Reduces Severe Exacerbations in Patients from China with Type 2 Asthma: A Subgroup Analysis of a Phase 3 Randomized Trial

J Asthma Allergy

Zhang Q, Fu X, Fang H, Lin J, Altincatal A, Huang Y, Kwah JH, Ledanois O, Zhong N

doi: 10.2147/JAA.S597499

COMMENTED

COPD

Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD

★ 3 Recommended and commented by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Thorax

Sadatsafavi M, Miravitlles M, Quint JK, Perugini V, Tavakoli H, Amegadzie JE, Alcazar Navarrete B, Respiratory Effectiveness Group (REG)-COPD working group

doi: 10.1136/thorax-2025-223770

Asthma

Benefits of CMAB007 in Chinese Patients Having Inadequately Controlled Moderate/Severe Asthma With Increased Total IgE: A Randomized Phase 3 Trial

Allergy Asthma Immunol Res

Lai K, Yan Z, Qian D, Zhang X, Bian T, Dai X, Li H, Lin L, Wang J, Wang L, Yang J, Hu Y, Li H, Nie X, Jin F, Li G, Sun S, Xu F, Zhao H, Chen Y, Liu C, Zhu H, Li J, Guo Y, Zhong N

doi: 10.4168/aair.2026.18.e1

COMMENTED

Asthma

A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE Study

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Eur Respir J

Boakye-Dankwa E, Kiddle SJ, Koo HN, Harper AR, Ambrose CS, Douglas IJ, Quint JK

doi: 10.1183/13993003.02196-2025

COPD

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials

Lancet

Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, Agustí À, Tal-Singer R, Han MK, Janssens W, Hanania NA, Nair P, Bremner P, Porpodis K, Shibata Y, Korn S, Yang T, Gordon O, Saenz R, Ng J, Cheung DS, Devine J, Grimbaldeston MA, Zhang W, Yang X, Mohan D, Vogelmeier CF, Brightling CE, ALIENTO and ARNASA investigators

doi: 10.1016/S0140-6736(26)00637-9

COMMENTED

Asthma

Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial

★ 3 Recommended and commented by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir J

Agarwal R, Chaudhary D, Gupta SN, Dhar R, Ranganadin P, Kumar R, Mohan A, Bajpai J, Davis R, Sehgal IS, Singh P, Biwas B, Mittal S, Mahendran AJ, Rajan B, Jadhav S, Vaidya A, Chhowala S, Sawant S, Gogtay J

doi: 10.1183/13993003.00058-2026

Further Publications

Adjunctive Effects of Pediatric Tuina on Symptoms, Inflammation, and Pulmonary Function in Children With Severe Pneumonia: A Randomized Controlled Trial

Pediatr Pulmonol

He T, Chen Y, Wen H, He L

doi: 10.1002/ppul.71404

COMMENTED

COPD

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended and commented by Dr Marcus Hesse, Faculty Member

Adv Ther

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F

doi: 10.1007/s12325-026-03514-6

RECOMMENDED

COPD

Prevention of COPD exacerbations with a mucosal trained immunity-based vaccine (MV130): a randomised phase 3 trial

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

Eur Respir J

Maestu LP, Rubio MC, Benedetti P, Matute WIG, Hermosa JLR, Álvarez-Sala JL, Martínez CJÁ, García MJB, Battles JS, Río FG, de Pedro JG, Fernández-Pérez C, Rodríguez-Sainz C, Pérez JG, de Miguel Diez J, Caballero R, Casanovas M, Subiza JL, Fernández-Cruz E

doi: 10.1183/13993003.00027-2026

Related content

Dupilumab Improves Lung Function and Reduces Severe Exacerbations in Patients from China with Type 2 Asthma: A Subgroup Analysis of a Phase 3 Randomized Trial

Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD

Benefits of CMAB007 in Chinese Patients Having Inadequately Controlled Moderate/Severe Asthma With Increased Total IgE: A Randomized Phase 3 Trial

A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE Study

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials

Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial

Adjunctive Effects of Pediatric Tuina on Symptoms, Inflammation, and Pulmonary Function in Children With Severe Pneumonia: A Randomized Controlled Trial

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Prevention of COPD exacerbations with a mucosal trained immunity-based vaccine (MV130): a randomised phase 3 trial